Daniel C Beachler1, Elizabeth L Yanik2, Brook I Martin3, Ruth M Pfeiffer2, Sohail K Mirza3, Richard A Deyo4, Eric A Engels2. 1. Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Daniel.beachler@nih.gov. 2. Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 3. The Dartmouth Institute for Health Policy and Clinical Practice (B.I.M. and S.K.M.) and the Department of Orthopaedic Surgery (S.K.M.), Dartmouth Geisel School of Medicine, Hanover, New Hampshire. 4. Departments of Family Medicine, Medicine, and Public Health and Preventative Medicine and the Oregon Institute of Occupational Health Sciences, Oregon Health & Science University, Portland, Oregon.
Abstract
BACKGROUND: Recombinant bone morphogenetic proteins (BMPs) are growth factors utilized in lumbar arthrodeses. Limited data from randomized trials suggest that BMP may increase cancer risk. We sought to evaluate cancer risk and mortality following the use of BMP in lumbar arthrodesis. METHODS: Within the linked Surveillance, Epidemiology, and End Results (SEER) Program-Medicare cohort, we conducted a case-cohort study of 7,278 individuals who were ≥65 years of age and had undergone a lumbar arthrodesis from 2004 to 2011. Of these patients, 3,627 were individuals in a 5% random subcohort of Medicare enrollees in SEER areas including 191 who developed cancer, and there were 3,651 individuals outside the subcohort who developed cancer. Weighted Cox proportional-hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for cancer on the basis of exposure to BMP. RESULTS: In the SEER-Medicare subcohort, 30.7% of individuals who underwent a lumbar arthrodesis received BMP. BMP was not associated with overall cancer risk in univariate analyses (HR, 0.92 [95% CI, 0.82 to 1.02]) or after adjustment for demographic characteristics, comorbidities, hospital size, history of cancer, and calendar year (adjusted HR, 0.94 [95% CI, 0.84 to 1.05]). Individual cancer types were also not significantly elevated (p > 0.05 for all) in BMP users compared with nonusers. In addition, BMP use was not associated with a new cancer in people who had cancer prior to undergoing lumbar arthrodesis (adjusted HR, 1.04 [95% CI, 0.71 to 1.52]) or with mortality after a cancer diagnosis (adjusted HR, 1.05 [95% CI, 0.93 to 1.19]). CONCLUSIONS: In a large population of elderly U.S. adults undergoing lumbar arthrodesis, BMP use was not associated with cancer risk or mortality. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
BACKGROUND: Recombinant bone morphogenetic proteins (BMPs) are growth factors utilized in lumbar arthrodeses. Limited data from randomized trials suggest that BMP may increase cancer risk. We sought to evaluate cancer risk and mortality following the use of BMP in lumbar arthrodesis. METHODS: Within the linked Surveillance, Epidemiology, and End Results (SEER) Program-Medicare cohort, we conducted a case-cohort study of 7,278 individuals who were ≥65 years of age and had undergone a lumbar arthrodesis from 2004 to 2011. Of these patients, 3,627 were individuals in a 5% random subcohort of Medicare enrollees in SEER areas including 191 who developed cancer, and there were 3,651 individuals outside the subcohort who developed cancer. Weighted Cox proportional-hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for cancer on the basis of exposure to BMP. RESULTS: In the SEER-Medicare subcohort, 30.7% of individuals who underwent a lumbar arthrodesis received BMP. BMP was not associated with overall cancer risk in univariate analyses (HR, 0.92 [95% CI, 0.82 to 1.02]) or after adjustment for demographic characteristics, comorbidities, hospital size, history of cancer, and calendar year (adjusted HR, 0.94 [95% CI, 0.84 to 1.05]). Individual cancer types were also not significantly elevated (p > 0.05 for all) in BMP users compared with nonusers. In addition, BMP use was not associated with a new cancer in people who had cancer prior to undergoing lumbar arthrodesis (adjusted HR, 1.04 [95% CI, 0.71 to 1.52]) or with mortality after a cancer diagnosis (adjusted HR, 1.05 [95% CI, 0.93 to 1.19]). CONCLUSIONS: In a large population of elderly U.S. adults undergoing lumbar arthrodesis, BMP use was not associated with cancer risk or mortality. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
Authors: D K McClish; L Penberthy; M Whittemore; C Newschaffer; D Woolard; C E Desch; S Retchin Journal: Am J Epidemiol Date: 1997-02-01 Impact factor: 4.897
Authors: Mick P Kelly; Jason W Savage; Søren M Bentzen; Wellington K Hsu; Scott A Ellison; Paul A Anderson Journal: J Bone Joint Surg Am Date: 2014-09-03 Impact factor: 5.284
Authors: Eugene J Carragee; Gilbert Chu; Rajat Rohatgi; Eric L Hurwitz; Bradley K Weiner; S Tim Yoon; Garet Comer; Branko Kopjar Journal: J Bone Joint Surg Am Date: 2013-09-04 Impact factor: 5.284
Authors: Eric A Engels; Ruth M Pfeiffer; Winnie Ricker; William Wheeler; Ruth Parsons; Joan L Warren Journal: Am J Epidemiol Date: 2011-08-04 Impact factor: 4.897
Authors: Jayesh P Thawani; Anthony C Wang; Khoi D Than; Chia-Ying Lin; Frank La Marca; Paul Park Journal: Neurosurgery Date: 2010-02 Impact factor: 4.654
Authors: C Ehret; R Aid-Launais; T Sagardoy; R Siadous; R Bareille; S Rey; S Pechev; L Etienne; J Kalisky; E de Mones; D Letourneur; J Amedee Vilamitjana Journal: PLoS One Date: 2017-09-14 Impact factor: 3.240
Authors: Silvia Minardi; Joseph S Fernandez-Moure; Dongmei Fan; Matthew B Murphy; Iman K Yazdi; Xuewu Liu; Bradley K Weiner; Ennio Tasciotti Journal: Pharmaceutics Date: 2020-02-01 Impact factor: 6.321